These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1503 related articles for article (PubMed ID: 29400023)

  • 21. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
    Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.
    Peng P; Zhu ZH; Zhong ZJ; Zheng K; Yang JX; Cao DY; Shen K
    Br J Radiol; 2015 Aug; 88(1052):20150109. PubMed ID: 25989698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
    García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
    Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Han EJ; O JH; Yoo IR; Kim YS; Kim MS; Kang JH; Choi WH
    Hell J Nucl Med; 2017; 20(2):134-140. PubMed ID: 28697190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Takekuma M; Maeda M; Ozawa T; Yasumi K; Torizuka T
    Int J Clin Oncol; 2005 Jun; 10(3):177-81. PubMed ID: 15990965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Mikkelsen MS; Petersen LK; Blaakaer J; Marinovskij E; Rosenkilde M; Andersen G; Bouchelouche K; Iversen LH
    Eur J Surg Oncol; 2021 Aug; 47(8):2134-2141. PubMed ID: 33812768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. To Enhance or Not to Enhance? The Role of Contrast Medium
    Massollo M; Fiz F; Bottoni G; Ugolini M; Paparo F; Puppo C; Provinciali N; Iacozzi M; Altrinetti V; Cistaro A; Cabria M; DeCensi A; Treglia G; Piccardo A
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34206116
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
    Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
    Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
    Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Tekinsoy B; Salepci T; Gumus M
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-Dimensional Image Fusion of
    Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
    J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
    Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
    Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.
    Hynninen J; Kemppainen J; Lavonius M; Virtanen J; Matomäki J; Oksa S; Carpén O; Grénman S; Seppänen M; Auranen A
    Gynecol Oncol; 2013 Nov; 131(2):389-94. PubMed ID: 23994535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
    Cohn DE; Hall NC; Povoski SP; Seamon LG; Farrar WB; Martin EW
    Gynecol Oncol; 2008 Aug; 110(2):152-7. PubMed ID: 18539314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.